Amit Sachdev, Executive Vice President and Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (NASDAQ:VRTX), sold shares of the company's common stock in two transactions on consecutive days in late February 2026.
On February 25, 2026, Sachdev disposed of 1,846 shares at $486.35 per share, a transaction valued at $897,802. The previous day, February 24, 2026, he sold 1,518 shares at $485.11 per share, for a total of $736,396. These sales were reported in a Form 4 filing with the Securities and Exchange Commission.
Following the two dispositions, Sachdev directly holds 55,570 shares of Vertex common stock. In addition to his direct holdings, he indirectly owns 882 shares through a 401(k) account and has 9,301 shares held in trust.
The reported sales were carried out pursuant to a company-approved 10b5-1 trading plan that was adopted on November 18, 2025.
Vertex's recent corporate results and analyst activity provide context to the timing of these trades. In its fourth-quarter 2025 report, the company posted $3.19 billion in revenue, a figure that narrowly exceeded the $3.18 billion forecast. Net income on a per-share basis was reported as $5.03 in earnings per share, which fell short of the $5.08 projection.
On the research front, Cantor Fitzgerald increased its price target for Vertex to $590 while maintaining an Overweight rating, citing confidence in the company's renal franchise. Separately, Oppenheimer upgraded Vertex from Perform to Outperform and set a price target of $540, attributing the move to optimism about Vertex's renal pipeline candidates, povetacicept and inaxaplin, as the company progresses toward 2026.
Market valuation commentary in the filing materials includes analysis from InvestingPro, which tracks over 1,400 U.S. equities and produces comprehensive research reports. According to InvestingPro analysis, Vertex presently appears overvalued relative to its Fair Value. The note states that investors can access 14 additional ProTips and detailed financial health metrics on the InvestingPro platform.
The transactions and the company's recent earnings and analyst coverage reflect concurrent developments in corporate insider activity, financial results, and external analyst sentiment. The Form 4 disclosure and the 10b5-1 plan adoption date remain the specifically reported mechanisms behind the share sales.